Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 310.00
Bid: 307.00
Ask: 312.00
Change: 0.00 (0.00%)
Spread: 5.00 (1.629%)
Open: 311.00
High: 314.00
Low: 303.00
Prev. Close: 310.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

7 Jul 2020 08:00

RNS Number : 2351S
Hutchison China Meditech Limited
07 July 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft

Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

 

Hutchison China MediTech Limited

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

X

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

X

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

General Atlantic Singapore HCM Pte. Ltd.

City and country of registered office (if applicable)

Singapore

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

06/07/2020

6. Date on which issuer notified (DD/MM/YYYY):

06/07/2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial in- struments

(total of 8.B 1 + 8.B 2)

 

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which

threshold was crossed or reached

 

2.81%

 

2.35%

 

5.16%

 

710,574,765

Position of previous notification (if applicable)

 

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or

reachedviii

A: Voting rights attached to shares

Class/type of shares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary Shares KYG4672N1198

20,000,000

2.81%

SUBTOTAL 8. A

20,000,000

2.81%

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

 

Type of financial instrument

 

Expiration datex

 

Exercise/ Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

 

% of voting rights

SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expiration datex

Exercise/ Conversion Period xi

Physical or cash settlementxii

Number of voting rights

 

% of voting rights

Warrants over

Ordinary Shares

January 3,

2022

At any time after July 2,

2020

Physical

16,666,670

2.35%

SUBTOTAL 8.B.2

16,666,670

2.35%

 

 

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or the

financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

 

X

 

 

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial in- struments if it equals or is higher than the

notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

GAP (Bermuda) Limited

5.16%

General Atlantic LLC

5.16%

General Atlantic GenPar (Bermuda), L.P.

 

5.16%

General Atlantic (Lux) S.à r.l.

5.16%

General Atlantic GenPar (Lux) SCSp, L.P.

 

5.16%

General Atlantic Part- ners (Bermuda) IV, L.P.

 

5.16%

General Atlantic Part- ners (Bermuda) EU, L.P.

 

5.16%

General Atlantic Part- ners (Lux) SCSp, L.P.

 

5.16%

GAP Coinvestments III, LLC

 

5.16%

GAP Coinvestments IV, LLC

 

5.16%

GAP Coinvestments V, LLC

 

5.16%

GAP Coinvestments CDA, L.P.

 

5.16%

General Atlantic Singa- pore Interholdco Ltd.

 

5.16%

 

 

General Atlantic Singa- pore Fund Pte. Ltd.

 

5.16%

General Atlantic Singa- pore HCM Pte. Ltd.

5.16%

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

 

 

 

11. Additional informationxvi

The warrants in Box B 2 have not been exercised, in part or whole, as of the below "Date of completion." Accordingly, the "Total number of voting rights of issuer" in Box 7 do not account for any issuance of the new voting shares, in part or whole, from the exercise of the warrants.

Once the warrants are exercised in full, assuming no other changes in the interests or the voting shares in the meantime, the "Total number of voting rights of issuer" in Box 7 will become 727,241,435. On that

basis, the ownership ordinary shares would represent 2.75%, the ownership of warrants would represent 2.29%, and the combined ownership of the ordinary shares and warrants would represent 5.04%.

 

 

Place of completion

Hong Kong, China

Date of completion

July 6, 2020

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLUBSNRRKUBRRR
Date   Source Headline
24th Mar 20177:00 amRNSAppointment of Director
21st Mar 201710:08 amRNSChi-Med to host R&D Briefings
20th Mar 20178:04 amRNSDirectors' Share Dealing
16th Mar 201711:25 amRNSGrant of Awards under Long Term Incentive Plan
13th Mar 20177:00 amRNSPublication of Form 20-F
13th Mar 20177:00 amRNSFinal Results
10th Mar 20178:11 amRNSSulfatinib Phase Ib/II Results Presented at ENETS
10th Mar 20177:18 amRNSSulfatinib Phase Ib/II Results Presented at ENETS
7th Mar 201711:49 amEQSEdison issues update on Hutchison China Meditech (HCM)
3rd Mar 20177:00 amRNSPositive Fruquintinib Pivotal Phase III Results
28th Feb 201710:20 amRNSChange of Directors
20th Feb 20177:00 amRNSStart of Phase II Savolitinib PSC trial in China
14th Feb 20177:07 amRNSInitiates Phase I of Novel FGFR Inhibitor HMPL-453
14th Feb 20177:00 amRNSSavolitinib PRCC Results Presentation at ASCO GU
6th Feb 20177:00 amRNSChi-Med to Announce 2016 Final Results
1st Feb 20177:00 amRNSChange of Directors
16th Jan 201710:48 amRNSChange of Directors
16th Jan 201710:11 amRNSChange of Directors
16th Jan 20177:30 amRNSFruquintinib Phase I/II Clinical Data at ASCO GI
16th Jan 20177:29 amRNSSulfatinib Phase II Study in 2nd Line BTC in China
16th Jan 20177:16 amRNSFruquintinib Combination Study in 1st-Line NSCLC
10th Jan 20177:00 amRNSChi-Med Initiates HMPL-523 Clinical Trials
30th Dec 20169:11 amRNSTotal Voting Rights
29th Dec 20167:40 amRNSBlocklisting Six Monthly Return
20th Dec 20167:18 amRNSDirector's Share Dealing
14th Dec 20167:14 amRNSDirector's Share Dealing
6th Dec 20167:00 amRNSHMPL-523 Pre-clinical Data Presented at ASH
30th Nov 20167:51 amRNSExercise of Share Options
30th Nov 20167:48 amRNSTotal Voting Rights
23rd Nov 20167:34 amRNSDirector's Share Dealing
23rd Nov 20167:30 amRNSChi-Med to Present Data at the 17th WCLC
23rd Nov 20167:08 amRNSChi-Med to Present Data at the at the 17th WCLC
14th Nov 20169:06 amRNSChi-Med Presents Ph I Clinical Data for HMPL-523
1st Nov 20162:57 pmRNSDirector's Share Dealing
31st Oct 20167:00 amRNSJoint Venture - US$59.5m Land Compensation Payment
12th Oct 20167:00 amRNSDirector's Share Dealing
9th Aug 20168:07 amRNSDirector's Share Dealing
2nd Aug 20168:18 amRNSChange of Non-executive Directors
2nd Aug 20167:00 amRNSChi-Med 2016 Interim Results
1st Aug 20167:21 amRNSChi-Med and AstraZeneca to Accelerate Savolitinib
5th Jul 20167:00 amRNSChi-Med to Announce 2016 HY Financial Results
29th Jun 20167:00 amRNSBlocklisting Six Monthly Return
20th Jun 20167:00 amRNSSavolitinib Global Phase II Trial Initiated
15th Jun 20168:09 amRNSAdditional Listing
31st May 20167:00 amRNSTotal Voting Rights
13th May 20167:00 amRNSEnrollment completion of Phase III fruquintinib
29th Apr 20167:00 amRNSTotal Voting Rights
27th Apr 20161:12 pmRNSResults of Annual General Meeting
13th Apr 20164:23 pmRNSExercise of Overallotment Option
31st Mar 20167:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.